Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update

- March 14th, 2018

Clearside Biomedical (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017, and provided an update on its development programs. As quoted in the press release: “Last week’s release of positive topline data from our pivotal … Continued

Clearside Biomedical (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017, and provided an update on its development programs.

As quoted in the press release:

“Last week’s release of positive topline data from our pivotal Phase 3 PEACHTREE trial represents the achievement of a major milestone for Clearside, and a critical inflection point, providing us with the requisite clinical information to begin the process of filing an NDA and the potential opportunity to transition from a clinical-stage to a commercial-stage company,” said Daniel H. White, Chief Executive Officer and President.  “Armed with our proprietary suprachoroidal approach to treatment, a focused pipeline of product candidates for multiple blinding eye diseases, extensive safety and efficacy data from our completed clinical trials, and a management team with a strong track record in both R&D and commercialization, we have never been more confident in Clearside’s ability to do great things in ophthalmology.  We have a number of additional key milestones coming up over the course of 2018, and look forward to updating you as we continue to progress.”

Click here to read the full press release.

 

New FREE Report: Investing in Psychedelics

   
What’s ahead for this exciting new segment? Learn more with our exclusive psychedelics report today.
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply